Raymond James & Associates’s Apyx Medical APYX Stock Holding History

Raymond James & Associates’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,325	Closed	-$196K	–	4119
2021 Q4	$196K	Buy	+15,325	New	+$214K	﹤0.01%	3708
2020 Q2	–	Sell	-170,868	Closed	-$613K	–	3522
2020 Q1	$613K	Buy	170,868 +9,460	+6%	+$63.5K	﹤0.01%	2283
2019 Q4	$1.37M	Sell	161,408 -4,630	-3%	-$33.4K	﹤0.01%	2075
2019 Q3	$1.12M	Buy	166,038 +8,750	+6%	+$62.1K	﹤0.01%	2132
2019 Q2	$1.06M	Buy	157,288 +25,000	+19%	+$136K	﹤0.01%	2181
2019 Q1	$835K	Hold	132,288	–	–	﹤0.01%	2314
2018 Q4	$857K	Hold	132,288	–	–	﹤0.01%	2173
2018 Q3	$939K	Buy	132,288 +14,288	+12%	+$79.4K	﹤0.01%	2294
2018 Q2	$513K	Hold	118,000	–	–	﹤0.01%	2664
2018 Q1	$350K	Hold	118,000	–	–	﹤0.01%	2792
2017 Q4	$307K	Buy	+118,000	New	+$368K	﹤0.01%	2819

Other funds holding APYX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Raymond James & Associates's APYX Position: Q1 2022 in Review

Raymond James & Associates sold out of Apyx Medical (APYX) in Q1 2022, closing a stake of 15,325 shares — an estimated $196K sold.

Raymond James & Associates first reported a position in APYX in Q4 2017 and held it in 11 quarters. The position peaked at $1.37M in Q4 2019. 71 funds tracked by Wall St. Rank hold APYX as of Q1 2022.

Raymond James & Associates reported no remaining Apyx Medical position as of Q1 2022 after selling out during the quarter.
Raymond James & Associates sold 15,325 Apyx Medical shares in Q1 2022, an estimated $196K.
Raymond James & Associates first reported a position in Apyx Medical in Q4 2017 and held it in 11 quarters.
Raymond James & Associates's Apyx Medical position peaked at $1.37M in Q4 2019.
71 funds tracked by Wall St. Rank held Apyx Medical as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.